 |
|
UMMS researchers isolate first 'neuroprotective' gene in patients with amyotrophic lateral sclerosis
May 12, 2009Genetic variant associated with an increase in survival by 14 months
WORCESTER, Mass. - A genetic variant that substantially improves survival of individuals with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, has been indentified by a consortium of researchers led by John Landers, PhD, Associate Professor of Neurology and Robert Brown, MD, DPhil, Chair and Professor of Neurology at the University of Massachusetts Medical School. Discovery of the KIFAP3 gene variant is reported in the Proceedings of the National Academy of Sciences.
"This report is the first to describe genetic factors that determine rate of progression in ALS," said Brown. "The finding reflects a truly international collaboration in which physicians and scientists from nearly 20 teams in several countries worked together to use new methods in genetics to understand ALS."
ALS is a progressive, neurodegenerative disorder affecting the motor neurons in the central nervous system. As motor neurons die, the brain's ability to send signals to the body's muscles is compromised. This leads to loss of voluntary muscle movement, paralysis and eventually death from respiratory failure. In 1993, a team of researchers led by Dr. Brown discovered the first gene linked to familial ALS, a protein anti-oxidant known as superoxide dismutase, or SOD1. Earlier this year, Dr. Brown and his colleagues discovered a mutation in the FUS/TLS gene which is estimated to account for 5 percent of inherited ALS cases. There are only four genes known, that when mutated, cause familial ALS. The KIFAP3 gene variant is the first to be linked with the rate of progression in ALS.
To isolate the KIFAP3 gene variant, a consortium of researchers from the U.S., Mexico, Israel and Europe examined more than 300,000 genetic variants in over 1,800 people with ALS and nearly 2,200 unaffected controls. The approach is based on the assumption that naturally occurring gene variations can influence both disease susceptibility and the way a disease runs its course once underway. During their search, the consortium detected a beneficial variant of the KIFAP3 gene which was associated with an increase in survival time of 40 to 50 percent.
Because survival with ALS is normally only three to five years, patients with the KIFAP3 gene variant experience a substantial improvement. In fact, the impact of this genetic variant is comparable to the effect of the only drug (Riluzole) now approved for use in the United States. More importantly, this genetic variant may potentially point the way to future drug development efforts.
While it's still unclear how the KIFAP3 gene variant alters the progression of ALS, researchers know that it is involved with a number of cellular processes, including the transport of essential molecules throughout the nerve cell.
"The favourable gene variant decreases levels of a motor protein complex in nerves," said Landers. "This complex transports substances through different parts of nerve cells. If we can understand the biological basis for the beneficial effect in ALS, it will potentially provide a target for the development of new ALS treatments."
Ammar Al-Chalabi, PhD, co-senior author of the study and Professor of Neurology and complex disease genetics at King's College, London added, "Treatments can now be directly designed to exploit the effect of this gene variation."
University of Massachusetts Medical School
ALS is a progressive, neurodegenerative disorder affecting the motor neurons in the central nervous system. As motor neurons die, the brain's ability to send signals to the body's muscles is compromised. This leads to loss of voluntary muscle movement, paralysis and eventually death from respiratory failure. In 1993, a team of researchers led by Dr. Brown discovered the first gene linked to familial ALS, a protein anti-oxidant known as superoxide dismutase, or SOD1. Earlier this year, Dr. Brown and his colleagues discovered a mutation in the FUS/TLS gene which is estimated to account for 5 percent of inherited ALS cases. There are only four genes known, that when mutated, cause familial ALS. The KIFAP3 gene variant is the first to be linked with the rate of progression in ALS.
To isolate the KIFAP3 gene variant, a consortium of researchers from the U.S., Mexico, Israel and Europe examined more than 300,000 genetic variants in over 1,800 people with ALS and nearly 2,200 unaffected controls. The approach is based on the assumption that naturally occurring gene variations can influence both disease susceptibility and the way a disease runs its course once underway. During their search, the consortium detected a beneficial variant of the KIFAP3 gene which was associated with an increase in survival time of 40 to 50 percent.
Because survival with ALS is normally only three to five years, patients with the KIFAP3 gene variant experience a substantial improvement. In fact, the impact of this genetic variant is comparable to the effect of the only drug (Riluzole) now approved for use in the United States. More importantly, this genetic variant may potentially point the way to future drug development efforts.
While it's still unclear how the KIFAP3 gene variant alters the progression of ALS, researchers know that it is involved with a number of cellular processes, including the transport of essential molecules throughout the nerve cell.
"The favourable gene variant decreases levels of a motor protein complex in nerves," said Landers. "This complex transports substances through different parts of nerve cells. If we can understand the biological basis for the beneficial effect in ALS, it will potentially provide a target for the development of new ALS treatments."
Ammar Al-Chalabi, PhD, co-senior author of the study and Professor of Neurology and complex disease genetics at King's College, London added, "Treatments can now be directly designed to exploit the effect of this gene variation."
University of Massachusetts Medical School
Amyotrophic Lateral Sclerosis Current Events and Amyotrophic Lateral Sclerosis News RSSSchizophrenia gene's role may be broader, more potent, than thought
UCSF scientists studying nerve cells in fruit flies have uncovered a new function for a gene whose human equivalent may play a critical role in schizophrenia.
Compound shows potential for slowing progression of ALS
A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice.
New guidelines identify best treatments to help ALS patients live longer, easier
New guidelines from the American Academy of Neurology identify the most effective treatments for amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease. The guidelines are published in the October 13, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.
Scientists encouraged by new mouse model's similarities to human ALS
A new mouse model of amyotrophic lateral sclerosis (ALS) closely resembles humans with the paralyzing disorder, researchers at Washington University School of Medicine in St. Louis report.
Amyotrophic lateral sclerosis may involve a form of sudden, rapid aging of the immune system
Premature aging of the immune system appears to play a role in the development of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to research scientists from the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center, the Weizmann Institute of Science in Israel, and Sheba Medical Center in Israel.
Physician-assisted suicide does not increase severity of depression, grief among family members
Unlike other forms of suicide, physician assisted death does not cause substantial regret, or a sense of rejection among surviving family members.
Mechanism related to the onset of various genetic diseases revealed
Researchers at the Department of Biochemistry and Molecular Biology of Universitat Autònoma de Barcelona (UAB) have revealed the process by which proteins with a tendency to cause conformational diseases such as amyotrophic lateral sclerosis, familial amyloidotic polyneuropathy, familial amyloidotic cardiomyopathy, etc. finally end up causing them.
Michigan Tech Mathematicians Identify Genes Linked to Lou Gehrig's Disease
Michigan Technological University researchers have linked three genes to the most common type of amyotrophic lateral sclerosis (ALS), generally known as Lou Gehrig's disease.
New Jefferson study may redefine how a chronic auto-immune disease is diagnosed
New research from Jefferson Hospital for Neuroscience (JHN) may redefine how Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is diagnosed.
Fatal brain disease at work well before symptoms appear
University of Florida scientists have discovered why a paralyzing brain disorder speeds along more rapidly in some patients than others - a finding that may finally give researchers an entry point toward an effective treatment for amyotrophic lateral sclerosis, often referred to as ALS or Lou Gehrig's disease.
More Amyotrophic Lateral Sclerosis Current Events and Amyotrophic Lateral Sclerosis News Articles
 |
Amyotrophic Lateral Sclerosis: A Guide for Patients and Families by M.D. Hiroshi Mitsumoto (Editor) This important book covers every aspect of living with ALS, from clinical features of the disease to an overview of symptom management to understanding its diagnosis. Major sections deal with overseeing medical care and rehabilitation, living with ALS, the disease’s advanced phase, end-of-life issues, and resources. Extensively revised and rewritten, this edition contains new chapters on the latest approaches to treating ALS symptoms, the use of noninvasive ventilators, multidisciplinary team care, new guidelines being developed by the American Academy of Neurology for patients with ALS, the use of riluzole (Rilutek), and more. |
 |
Amyotrophic Lateral Sclerosis (American Academy of Neurology) by M.D. Robert G. Miller (Author), M.D. Deborah Gelinas (Author), RN Patricia O'Connor (Author) ALS, also known as Lou Gehrig's disease, cannot be cured, but treatments are now available that can make a major difference in prolonging and enhancing life. Written by clinicians who manage one of the leading ALS centers in the world, this book guides readers through an understanding what ALS is, how it is diagnosed, the management of symptoms, and the drugs that are available to treat the underlying disease process. Chapters cover topics that include nutrition and swallowing; speech, communication, and computer access; mobility; breathing and sleeping; end-of-life care; and much more, including insurance issues and practical tips. Chapters from leading ALS organizations offer a broad list of support services, publications, websites, and other resources. |
 |
Amyotrophic Lateral Sclerosis Awareness Ribbon Mouse Pad by MyHeritageWear.com The Amyotrophic Lateral Sclerosis proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Amyotrophic Lateral Sclerosis than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Amyotrophic Lateral Sclerosis mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
|
Ecological Formulas Sphingolin Caps 60's (Use of This Product May Benefit Those with Myelin Diseases Such As Multiple Sclerosis (Ms) and Amyotrophic Lateral Sclerosis (Als -Lou Gehrig's Disease) by Ecological Formulas This product, from Ecological Formulas, is an extract of bovine myelin sheath and is a rich source of myelin protective proteins. Use of this product may benefit those with myelin diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS -Lou Gehrig's Disease) | |
 |
The Man Who Learned to Fall Directed By: Garry Beitel Also With: Garry Beitel and Barry Lazar (Producer) The Man Who Learned to Fall is a feature documentary about a gifted writer and sought after teacher who celebrates the wonder of life even as he is slowly dying of a fatal neuromuscular condition. At the age of 35, Philip Simmons learned that he had ALS or Lou Gehrigs disease. Married, with two young children and a promising career as an English Professor and writer, he was told that he had less than five years to live. Filmed in the foothills of the White Mountains of New Hampshire, this intimate portrait of Phil and his family captures the witty eloquence and poetic grace of a dying man and his heroic journey. As his muscles deteriorate and his body becomes increasingly paralyzed, Philip Simmons continues to wrestle joy from heartbreak, again and again and again, at each stage of his... |
 |
Body & Soul Also With: Warner Bros. (Producer) |
 |
ALS Awareness Key Chain, Oregon & SW Washington Chapter by Abernook Show support and spread ALS awareness with the swarovski crystal and bali silver keychain. This bracelet is designed using Swarovski crystals and Bali silver. Spouses, family and friends can now show their support and spread knowledge and awareness about the disease. A portion of the proceeds is being given to the ALS Association. Also available, ALS Bracelet, Earrings and Purse Charm |
 |
ALS Awareness Loop, ALSA New Mexico Chapter by Abernook This mini bracelet was designed to adorn wheelchairs, rear view mirrors, back packs and purses (as a purse charm). Now you can show your support any time. Made with Swarovski Crystals, Bali Silver along with a silver awareness charm. A portion of the proceeds is being donated to the ALS Chapters. |
 |
ALS Awareness Earrings, Oregon & SW Washington Chapter by Abernook Made with Swarovski Crystals and Bali Silver, you can now show your support through these ALS earrings. A portion of the proceeds goes to the ALS Association to provide aid in research, patient care, family care and support. Also available ALS bracelet and Purse Charm |
 |
Amyotrophic Lateral Sclerosis, Second Edition by Robert H. Brown Jr. (Editor), Michael Swash (Editor), Piera Pasinelli (Editor) Amyotrophic lateral sclerosis or motor neurone disease is one of the most debilitating and devastating of the neurological diseases. The only comprehensive textbook available on the topic, this completely reorganized and expanded new edition examines all aspects of ALS from pathology to patient care and provides the reader with a ready reference to help with the difficulties encountered in patient diagnosis and treatment. Undoubtedly an important work in the field, this book will be of great interest to clinical neurologists and trainees, and to all those concerned with the care of people with ALS. |
| © 2009 BrightSurf.com |